Gilead Sciences, Inc. vs Arrowhead Pharmaceuticals, Inc.: Annual Revenue Growth Compared

Biotech Giants: Gilead vs. Arrowhead Revenue Growth

__timestampArrowhead Pharmaceuticals, Inc.Gilead Sciences, Inc.
Wednesday, January 1, 201417500024890000000
Thursday, January 1, 201538200032639000000
Friday, January 1, 201615833330390000000
Sunday, January 1, 20173140770926107000000
Monday, January 1, 20181614232122127000000
Tuesday, January 1, 201916879557722449000000
Wednesday, January 1, 20208799206624689000000
Friday, January 1, 202113828700027305000000
Saturday, January 1, 202224323100027281000000
Sunday, January 1, 202324073500027116000000
Monday, January 1, 2024355100028754000000
Loading chart...

Unleashing the power of data

A Tale of Two Biotechs: Gilead Sciences vs. Arrowhead Pharmaceuticals

In the dynamic world of biotechnology, revenue growth is a key indicator of a company's success and innovation. Over the past decade, Gilead Sciences, Inc. and Arrowhead Pharmaceuticals, Inc. have showcased contrasting trajectories in their annual revenue growth.

Gilead Sciences, a giant in the biotech industry, has consistently maintained a robust revenue stream, peaking in 2015 with a staggering $32.6 billion. Despite a slight decline in subsequent years, Gilead's revenue remained strong, averaging around $27 billion annually from 2016 to 2023.

In contrast, Arrowhead Pharmaceuticals, a smaller player, has demonstrated impressive growth, albeit from a lower base. From a modest $175,000 in 2014, Arrowhead's revenue surged to over $240 million by 2023, marking a phenomenal growth rate of over 137,000%.

This comparison highlights the diverse strategies and market positions of these two companies, offering valuable insights into the biotech sector's evolving landscape.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025